China Pharma Holdings, Inc. (CPHI)
NYSE American
Price as at 2 Oct 2026, 12:04 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
China Pharma Holdings, Inc. trades at $0.65. We do not hold enough of the inputs to value this company with the confidence the estimate implies, so we publish no fair value for it rather than a number we would not defend.
About China Pharma Holdings, Inc.
China Pharma Holdings, Inc. develops, manufactures, and markets pharmaceutical products for human use in the People's Republic of China. The company provides products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate injection to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Ozagrel Sodium to treat acute thrombotic cerebral infarction and dyskinesia; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection for edema diseases, hypertension, acute renal failure, hyperkalemia, hypercalcemia, and acute drug poisoning; and Candesartan for hypertension. It offers Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and Pseudophedrine Hydrochlorida sustained release tablets, as well as Hepatocyte growth-promoting factors, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. In addition, the company provides Vitamin B6 injection; Granisetron Hydrochloride injection for nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks. It supplies its products to hospitals and OTC pharmacies through provincial and municipal pharmaceutical logistics companies. The company is based in Haikou, the People's Republic of China.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
Super investor ownership
2 of the funds we track reported a position in their latest SEC 13F filing. Largest first:
- Ken Griffin, CITADEL ADVISORS LLC$82.8K · 0.0% of book
- Renaissance Technologies, RENAISSANCE TECHNOLOGIES LLC$9.9K · 0.0% of book
A word of warning on reading these figures: a 13F reports the market value of a holding, so a fund that traded nothing at all still appears to have sold when the price fell. We found 102 companies where the standard reading gives the opposite answer. Only the share count is honest.
Common questions
Which funds own CPHI?
2 of the institutions we track reported a position in CPHI in their most recent SEC 13F filing. A 13F is filed up to 45 days after quarter end, so it tells you what a fund held then, not what it holds now.
Where does SteadyShares get its CPHI data?
Fundamentals for CPHI come from company filings and exchange data, as listed on NYSE American; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 2 Oct 2026, 12:04 UTC and is delayed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for CPHI, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.